Share

    


In This Section

Overview

Monitoring a patient’s measurable residual disease (MRD) at various points throughout active treatment and into remission provides important personalized insights into the effectiveness of a given therapy and may be used to predict which patients are at risk of relapse. Testing for MRD can shape treatment choices and overall patient management to achieve better outcomes.

The Association of Community Cancer Centers (ACCC) is hosting a webinar with faculty who are experts in the field of hematologic malignancies.

MRD Clinical Updates in Chronic Lymphocytic Leukemia


Wed, December 16, 2020
1:30 PM to 2:15 PM (Eastern Standard Time)

This webinar provides the multidisciplinary cancer team with important and practical information for the assessment of measurable residual disease (MRD) as part of routine clinical practice for their patients with Chronic Lymphocytic Leukemia (CLL).

The presentation will be valuable for understanding the impact of MRD on treatment decisions and practice patterns, which has promise to lead to major improvements in outcomes for CLL patients in the very near future.

Faculty:

  • John M. Pagel, MD, PhD, Chief of Hematologic Malignancies; Director, Stem Cell Transplantation, Swedish Cancer Institute
  • Cecilia Arana Yi, MD, Senior Associate Consultant; Director of Leukemia Services, Hematology/Oncology, Department of Internal Medicine, Mayo Clinic
  • Amy Goodrich, RN, MSN, CRNP-AC, Research Associate, The Johns Hopkins School of Medicine; Nurse Practitioner, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (Moderator)

Register

This project is supported by Adaptive Biotechnologies.

 

For more information on this project, please contact the ACCC Provider Education department.

Our Supporter

Adaptive-Biotech-logo-215x80

This project is supported by Adaptive Biotechnologies.